Skip to main content

Table 2 Summary of tablet acceptance for dogs administered Credelio Plus or Nexgard Spectra tablets in the safety population

From: Field study to investigate the effectiveness and safety of a novel orally administered combination drug product containing milbemycin oxime and lotilaner (Credelio® Plus) against natural intestinal nematode infections in dogs presented as veterinary patients in Europe

Treatment group Number of dogs Number of dogs consuming tabletfree choice (%) Number of dogs manually dosed (pilled) (%)
Credelio Plus 355 292 (82.3%) 63 (17.7%)
Nexgard Spectra 151 122 (80.8%) 29 (19.2%)